Lavinia Racaru-Vija
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 23, 2026
Myelodysplastic Syndrome Related to Successful Treatment With 177 Lu-PSMA for Metastatic Castration-Refractory Prostate Cancer.
Journal: Clinical nuclear medicine
Published: May 21, 2024
Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging.
Journal: Clinical nuclear medicine
Published: April 26, 2019
The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.
Journal: The Journal of steroid biochemistry and molecular biology
Published: March 21, 2019
Incidental Finding of Intrathyroid Metastases of Prostatic Cancer on 18F-Choline PET/CT.
Journal: Clinical nuclear medicine
Published: December 06, 2018
Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
Journal: Nuclear medicine communications
Published: May 24, 2018
Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response.
Journal: Nuclear medicine communications
Published: July 19, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026